nach oben

Current Cardiology Reports

Erschienen in:

01.11.2020 | Heart Failure (HJ Eisen, Section Editor)

Advances in the Genetics and Genomics of Heart Failure

verfasst von: Nosheen Reza, Anjali Tiku Owens

Erschienen in: Current Cardiology Reports | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to provide an update on the recent advances in the genetics and genomics of dilated cardiomyopathy and heart failure.

Recent Findings

Over the last decade, the approach to the discovery of the genetic contribution to heart failure has evolved from investigation of rare variants implicated in Mendelian cardiomyopathies through linkage studies and candidate gene studies to the exploration of the contribution of common variants through large-scale genome-wide association and genome-first studies.

Summary

The combination and integration of multiple of case-control heart failure cohorts, refinement of the heart failure phenotype, and utilization of large biobanks linked to electronic health records have advanced the understanding of the heritability of heart failure.

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–528. https://doi.org/10.1161/CIR.0000000000000659.CrossRefPubMed

Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13:368–78. https://doi.org/10.1038/nrcardio.2016.25.CrossRefPubMedPubMedCentral

Glynn P, Lloyd-Jones DM, Feinstein MJ, Carnethon M, Khan SS. Disparities in cardiovascular mortality related to heart failure in the United States. J Am Coll Cardiol. 2019;73:2354–5. https://doi.org/10.1016/j.jacc.2019.02.042.CrossRefPubMed

Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50. https://doi.org/10.1001/jama.292.3.344.CrossRefPubMed

Jarcho JA, McKenna W, Pare JA, Solomon SD, Holcombe RF, Dickie S, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. 1989;321:1372–8. https://doi.org/10.1056/NEJM198911163212005.CrossRefPubMed

Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108–14. https://doi.org/10.1056/NEJM199204233261703.CrossRefPubMed

Reza N, Musunuru K, Owens AT. From hypertrophy to heart failure: what is new in genetic cardiomyopathies. Curr Heart Fail Rep. 2019;16:157–67. https://doi.org/10.1007/s11897-019-00435-0.CrossRefPubMedPubMedCentral

Lee DS, Pencina MJ, Benjamin EJ, Wang TJ, Levy D, O’Donnell CJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med. 2006;355:138–47. https://doi.org/10.1056/NEJMoa052948.CrossRefPubMed

Mahmood SS, Wang TJ. The epidemiology of congestive heart failure: the Framingham heart study perspective. Glob Heart. 2013;8:77–82. https://doi.org/10.1016/j.gheart.2012.12.006.CrossRefPubMed

10.

McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441–6. https://doi.org/10.1056/NEJM197112232852601.CrossRefPubMed

11.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239. https://doi.org/10.1016/j.jacc.2013.05.019.CrossRefPubMed

12.

Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807–16. https://doi.org/10.1161/CIRCULATIONAHA.106.174287.CrossRefPubMed

13.

Kinnamon DD, Morales A, Bowen DJ, Burke W, Hershberger RE, DCM Consortium*. Toward genetics-driven early intervention in dilated cardiomyopathy: design and implementation of the DCM precision medicine study. Circ Cardiovasc Genet. 2017;10:10. https://doi.org/10.1161/CIRCGENETICS.117.001826.CrossRef

14.

Cappola TP, Li M, He J, Ky B, Gilmore J, Qu L, et al. Common variants in HSPB7 and FRMD4B associated with advanced heart failure. Circ Cardiovasc Genet. 2010;3:147–54. https://doi.org/10.1161/CIRCGENETICS.109.898395.CrossRefPubMedPubMedCentral

15.

Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet. 2010;3:256–66. https://doi.org/10.1161/CIRCGENETICS.109.895763.CrossRefPubMedPubMedCentral

16.

Morrison AC, Felix JF, Cupples LA, Glazer NL, Loehr LR, Dehghan A, et al. Genomic variation associated with mortality among adults of European and African ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium. Circ Cardiovasc Genet. 2010;3:248–55. https://doi.org/10.1161/CIRCGENETICS.109.895995.CrossRefPubMedPubMedCentral

17.

Stark K, Esslinger UB, Reinhard W, Petrov G, Winkler T, Komajda M, et al. Genetic association study identifies HSPB7 as a risk gene for idiopathic dilated cardiomyopathy. PLoS Genet. 2010;6:e1001167. https://doi.org/10.1371/journal.pgen.1001167.CrossRefPubMedPubMedCentral

18.

Villard E, Perret C, Gary F, Proust C, Dilanian G, Hengstenberg C, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J. 2011;32:1065–76. https://doi.org/10.1093/eurheartj/ehr105.CrossRefPubMedPubMedCentral

19.

Horne BD, Rasmusson KD, Alharethi R, Budge D, Brunisholz KD, Metz T, et al. Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet. 2011;4:359–66. https://doi.org/10.1161/CIRCGENETICS.110.959205.CrossRefPubMed

20.

Fox ER, Musani SK, Barbalic M, Lin H, Yu B, Ogunyankin KO, et al. Genome-wide association study of cardiac structure and systolic function in African Americans: the Candidate Gene Association Resource (CARe) study. Circ Cardiovasc Genet. 2013;6:37–46. https://doi.org/10.1161/CIRCGENETICS.111.962365.CrossRefPubMed

21.

Meder B, Rühle F, Weis T, Homuth G, Keller A, Franke J, et al. A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. Eur Heart J. 2014;35:1069–77. https://doi.org/10.1093/eurheartj/eht251.CrossRefPubMed

22.

Smith JG, Felix JF, Morrison AC, Kalogeropoulos A, Trompet S, Wilk JB, et al. Discovery of genetic variation on chromosome 5q22 associated with mortality in heart failure. PLoS Genet. 2016;12:e1006034. https://doi.org/10.1371/journal.pgen.1006034.CrossRefPubMedPubMedCentral

23.

Aragam KG, Chaffin M, Levinson RT, McDermott G, Choi S-H, Shoemaker MB, et al. Phenotypic refinement of heart failure in a national biobank facilitates genetic discovery. Circulation. 2018;139:489–501. https://doi.org/10.1161/CIRCULATIONAHA.118.035774.CrossRef

24.

• Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun. 2020;11:163. https://doi.org/10.1038/s41467-019-13690-5This study reports findings from the largest heart failure genome-wide association study to date.CrossRefPubMedPubMedCentral

25.

•• Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–9. https://doi.org/10.1038/s41586-018-0579-zThis manuscript summarizes the existing and planned content of the UK Biobank.CrossRefPubMedPubMedCentral

26.

Abul-Husn NS, Kenny EE. Personalized medicine and the power of electronic health records. Cell. 2019;177:58–69. https://doi.org/10.1016/j.cell.2019.02.039.CrossRefPubMedPubMedCentral

27.

Herman DS, Lam L, Taylor MRG, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366:619–28. https://doi.org/10.1056/NEJMoa1110186.CrossRefPubMedPubMedCentral

28.

Akinrinade O, Alastalo T-P, Koskenvuo JW. Relevance of truncating titin mutations in dilated cardiomyopathy. Clin Genet. 2016;90:49–54. https://doi.org/10.1111/cge.12741.CrossRefPubMed

29.

Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015;36:1123–35. https://doi.org/10.1093/eurheartj/ehu301.CrossRefPubMed

30.

Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016;374:233–41. https://doi.org/10.1056/NEJMoa1505517.CrossRefPubMedPubMedCentral

31.

Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguchía J, et al. Genetic etiology for alcohol-induced cardiac toxicity. J Am Coll Cardiol. 2018;71:2293–302. https://doi.org/10.1016/j.jacc.2018.03.462.CrossRefPubMedPubMedCentral

32.

Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM, et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation. 2019;140:31–41. https://doi.org/10.1161/CIRCULATIONAHA.118.037934.CrossRefPubMedPubMedCentral

33.

Haggerty CM, Damrauer SM, Levin MG, Birtwell D, Carey DJ, Golden AM, et al. Genomics-first evaluation of heart disease associated with Titin-truncating variants. Circulation. 2019;140:42–54. https://doi.org/10.1161/CIRCULATIONAHA.119.039573.CrossRefPubMedPubMedCentral

34.

Pirruccello JP, Bick A, Chaffin M, Aragam KG, Choi SH, Lubitz SA, et al. Titin truncating variants in adults without known congestive heart failure. J Am Coll Cardiol. 2020;75:1239–41. https://doi.org/10.1016/j.jacc.2020.01.013.CrossRefPubMedPubMedCentral

35.

Pirruccello JP, Bick A, Wang M, Chaffin M, Friedman S, Yao J, et al. Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. Nat Commun. 2020;11:2254. https://doi.org/10.1038/s41467-020-15823-7.CrossRefPubMedPubMedCentral

36.

Park J, Levin MG, Haggerty CM, Hartzel DN, Judy R, Kember RL, et al. A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. Genet Med Off J Am Coll Med Genet. 2020;22:102–11. https://doi.org/10.1038/s41436-019-0625-8.CrossRef

37.

Oni-Orisan A, Lanfear DE. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev. 2014;22:193–8. https://doi.org/10.1097/CRD.0000000000000028.CrossRefPubMedPubMedCentral

38.

Cresci S, Pereira NL, Ahmad F, Byku M, de Las FL, Lanfear DE, et al. Heart failure in the era of precision medicine: a scientific statement from the American Heart Association. Circ Genomic Precis Med. 2019;12:458–85. https://doi.org/10.1161/HCG.0000000000000058.CrossRef

39.

O’Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, et al. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. PLoS One. 2012;7:e44324. https://doi.org/10.1371/journal.pone.0044324.CrossRefPubMedPubMedCentral

40.

Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013;6:137–43. https://doi.org/10.1161/CIRCEP.111.969618.CrossRefPubMed

41.

Kao DP, Davis G, Aleong R, O’Connor CM, Fiuzat M, Carson PE, et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013;15:324–33. https://doi.org/10.1093/eurjhf/hfs181.CrossRefPubMed

42.

Rau T, Düngen H-D, Edelmann F, Waagstein F, Lainščak M, Dimković S, et al. Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther. 2012;92:21–8. https://doi.org/10.1038/clpt.2012.18.CrossRefPubMed

43.

Fiuzat M, Neely ML, Starr AZ, Kraus WE, Felker GM, Donahue M, et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail. 2013;15:258–66. https://doi.org/10.1093/eurjhf/hfs175.CrossRefPubMed

44.

Cuoco MAR, Pereira AC, de FA da Mota G, Krieger JE, Mansur AJ. Genetic polymorphism, medical therapy and sequential cardiac function in patients with heart failure. Arq Bras Cardiol. 2008;90:252–6.CrossRefPubMed

45.

Kohno M, Yokokawa K, Minami M, Kano H, Yasunari K, Hanehira T, et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med. 1999;106:544–9. https://doi.org/10.1016/s0002-9343(99)00067-4.CrossRefPubMed

46.

Wu C-K, Luo J-L, Tsai C-T, Huang Y-T, Cheng C-L, Lee J-K, et al. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J. 2010;10:46–53. https://doi.org/10.1038/tpj.2009.39.CrossRefPubMed

47.

McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, Mathier M, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004;44:2019–26. https://doi.org/10.1016/j.jacc.2004.08.048.CrossRefPubMed

48.

Aarnoudse A-JLHJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RHN, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008;18:299–305. https://doi.org/10.1097/FPC.0b013e3282f70458.CrossRefPubMed

49.

Vormfelde SV, Brockmöller J. The genetics of loop diuretic effects. Pharmacogenomics J. 2012;12:45–53. https://doi.org/10.1038/tpj.2010.68.CrossRefPubMed

Titel: Advances in the Genetics and Genomics of Heart Failure
verfasst von: Nosheen Reza
Anjali Tiku Owens
Publikationsdatum: 01.11.2020
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 11/2020
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-020-01385-z

Neu im Fachgebiet Kardiologie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2020

Medication Non-adherence: a Major Cause of Resistant Hypertension

Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?

Point-of-Care Ultrasound

Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone